| Name | interleukin (protein family or complex) |
|---|---|
| Synonyms | Interleukin; Interleukins; interleukin receptor; interleukin receptors |
| Name | MAA |
|---|---|
| CAS | methylarsonic acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 15472138 | Zhong H, Belardinelli L, Maa T, Zeng D: Synergy between A2B receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol. 2005 Jan;32(1):2-8. Epub 2004 Oct 7. Under the normoxic condition, and its stable analog, 5'-(N-ethylcarboxamido)- via activation of A2B receptors, increased the release of interleukin (IL)-6 by 14-fold and induced the differentiation of human lung fibroblasts to myofibroblasts. |
1(0,0,0,1) | Details |
| 11008078 | Aiba M, Takeyoshi I, Sunose Y, Iwazaki S, Tsutsumi H, Ohwada S, Tomizawa N, Oriuchi N, Matsumoto K, Morishita Y: FR167653 ameliorates pulmonary damage in ischemia-reperfusion injury in a canine lung transplantation model. J Heart Lung Transplant. 2000 Sep;19(9):879-86. BACKGROUND: Interleukin (IL)-1 and tumor necrosis factor-alpha (TNF-alpha) are recognized as important factors in ischemia-reperfusion (I/R) injury. |
1(0,0,0,1) | Details |
| 7904182 | Kim TS, Collins MK, Cohen EP: Independent cell types are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):298-304. Cellular antimelanoma immune responses developed during the coincubation of spleen cells from naive C57BL/6 mice (H-2b) with LM mouse fibroblasts (H-2k) genetically modified to express melanoma-associated antigens (MAA) and to secrete interleukin (IL)-2 (RLBA-IL-2 cells). |
1(0,0,0,1) | Details |
| 18310089 | Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH: Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis. 2008 Aug;29(8):1483-92. Epub 2008 Feb 28. Interleukin (IL)-6 plays an important role in osteoclastogenesis. |
1(0,0,0,1) | Details |
| 18435575 | Fong YC, Maa MC, Tsai FJ, Chen WC, Lin JG, Jeng LB, Yang RS, Fu WM, Tang CH: Osteoblast-derived TGF-beta1 stimulates IL-8 release through AP-1 and NF-kappaB in human cancer cells. J Bone Miner Res. 2008 Jun;23(6):961-70. It has been reported that the chemokine interleukin (IL)-8 is a potent and direct activator of osteoclastic differentiation and bone resorption. |
1(0,0,0,1) | Details |
| 3265967 | Maezawa N, Yano A: Requirement of Ia-positive nylon wool adherent cells for activation of cytotoxic T-lymphocytes specific to melanocyte-associated antigens in patients with Vogt-Koyanage-Harada's disease. Jpn J Ophthalmol. 1988;32(3):348-57. Moreover, the cytotoxic activity of nylon wool NAC was augmented by the addition of interleukins instead of DR-positive AC. |
1(0,0,0,1) | Details |
| 15648952 | Galmarini CM: (subcutaneous) Maxim. Curr Opin Investig Drugs. 2004 Dec;5(12):1298-310. Maxim is developing a subcutaneous formulation of (Ceplene, formerly known as Maxamine) for use as an adjuvant with interleukin (IL)-2 therapy for the potential treatment of metastatic melanoma, hepatitis C virus infection, acute myelogenous leukemia and renal cell carcinoma. In November 2003, Maxim submitted an MAA to the EMEA for malignant melanoma in combination with IL-2. |
1(0,0,0,1) | Details |